New hope for bladder cancer: targeted drug combo aims to boost survival

NCT ID NCT07608224

Not yet recruiting Disease control Sponsor: West China Hospital Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tests whether a combination of disitamab vedotin (a targeted drug) and toripalimab (an immunotherapy) works better than standard chemotherapy plus immunotherapy for people with HER2-positive muscle-invasive bladder cancer. About 240 participants will receive treatment before and after bladder removal surgery. The main goal is to see if the new combo improves how long patients live without their cancer returning or spreading.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: disitamab vedotin (RC48) plus toripalimab
What this could lead to: If successful, this could offer a more targeted, less toxic treatment option for HER2-positive bladder cancer, potentially improving survival and reducing recurrence.
What could go wrong: This is an early-phase (2/3) trial with only 240 participants, so results may not apply to all patients. The drug combo may cause side effects or not outperform standard chemo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MUSCLE-INVASIVE BLADDER CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

infiltrating bladder urothelial carcinoma urinary bladder neoplasm Urinary Bladder Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

URINARY BLADDER NEOPLASMS

More trials for these conditions

Other studies related to the condition(s) this trial covers.